FDA
- Status: approved
🇺🇸 IPV at 14 and 22 weeks of age, RotaTeq in United States
IPV at 14 and 22 weeks of age, RotaTeq (IPV at 14 and 22 weeks of age, RotaTeq) regulatory status in United States.
Marketing authorisation
IPV at 14 and 22 weeks of age, RotaTeq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is IPV at 14 and 22 weeks of age, RotaTeq approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for IPV at 14 and 22 weeks of age, RotaTeq in United States?
Centers for Disease Control and Prevention is the originator. The local marketing authorisation holder may differ — check the official source linked above.